Journal
EPILEPSIA
Volume 51, Issue 6, Pages 958-967Publisher
WILEY-BLACKWELL
DOI: 10.1111/j.1528-1167.2009.02496.x
Keywords
Antiepileptic drugs; Epilepsy; Partial-onset seizures; Randomized controlled trial; Lacosamide
Categories
Funding
- SCHWARZ BIOSCIENCES, Inc.
- UCB Group (Research Triangle Park, NC, U.S.A.)
- Prescott Medical Communications Group (Chicago, IL, U.S.A.)
- Schwarz Pharma A.G.
- GlaxoSmithKline plc.
- Valeant
- Eisai Inc.
- Ortho-McNeil.
- Medtronics, Inc
- NeuroPace, Inc.
- Johnson Johnson Inc.
- Marinus Pharmaceuticals, Inc.
Ask authors/readers for more resources
P>Purpose: To evaluate the efficacy and safety of lacosamide (400 and 600 mg/day) as adjunctive treatment in patients with uncontrolled partial-onset seizures taking one to three concomitant antiepileptic drugs (AEDs). Methods: This multicenter, double-blind, placebo-controlled trial randomized patients 1:2:1 to placebo, lacosamide 400 mg, or lacosamide 600 mg/day. After an 8-week baseline period, patients began treatment with placebo or lacosamide 100 mg/day, were force-titrated weekly (100 mg/day increments) to the target dose, and entered a 12-week maintenance period. Results: A total of 405 patients were randomized and received trial medication. Most (82.1%) were taking two to three concomitant AEDs. Median percent reductions in seizure frequency per 28 days from baseline to maintenance (intention-to-treat, ITT) were 37.3% for lacosamide 400 mg/day (p = 0.008) and 37.8% for lacosamide 600 mg/day (p = 0.006) compared to 20.8% for placebo, with responder rates of 38.3% and 41.2%, respectively, compared to placebo (18.3%, p < 0.001; ITT). Patients randomized to lacosamide showed large reductions in secondarily generalized tonic-clonic seizures, with median percent reductions in seizure frequency of 59.4% for lacosamide 400 mg/day and 93.0% for lacosamide 600 mg/day compared to 14.3% for placebo, and responder rates of 56.0% and 70.2% compared to placebo (33.3%). Dose-related adverse events included dizziness, nausea, and vomiting. Discussion: Adjunctive treatment with lacosamide 400 and 600 mg/day reduced seizure frequency for patients with uncontrolled partial-onset seizures. Lacosamide 400 mg/day provided a good balance of efficacy and tolerability; lacosamide 600 mg/day may provide additional benefit for some patients as suggested by secondary efficacy analyses, including response in patients with secondarily generalized tonic-clonic seizures.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available